Apoptosis-related molecules in blood in multiple sclerosis

Journal of Neuroimmunology

Volumn 205, Issue 1-2, 2008, Pages 135-141

  Rinta, Sanna ^a   Kuusisto, Hanna ^b   Raunio, Minna ^b   Paalavuo, Raija ^a   Levula, Mari ^a,b   Lehtimäki, Terho ^a,b   Elovaara, Irina ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Biological markers; Fas; Fas ligand macrophage migration inhibitory factor; Interferon ; Multiple sclerosis; TNF related apoptosis inducing ligand

Indexed keywords

BETA1A INTERFERON; FAS ANTIGEN; FAS LIGAND; INTERFERON BETA SERINE; MESSENGER RNA; MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; APOPTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RNA, MESSENGER; STATISTICS AS TOPIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTORS;

EID: 56349129669     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.09.002     Document Type: Article

References (33)

1. Aktas O., Smorodchenko A., Brocke S., Infante-Duarte C., Topphoff U.S., Vogt J., Prozorovski T., Meier S., Osmanova V., Pohl E., Bechmann I., Nitsch R., and Zipp F. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46 (2005) 421-432
2. Arbour N., Rastikerdar E., McCrea E., Lapierre Y., Dorr J., Bar-Or A., and Antel J.P. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate. Mult. Scler. 11 (2005) 652-657
3. Askenasy N., Yolcu E.S., Yaniv I., and Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105 (2005) 1396-1404
4. Bilinska M., Frydecka I., Podemski R., and Gruszka E. Fas expression on T cells and sFas in relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 107 (2003) 387-393
5. Boylan M.T., Crockard A.D., McDonnell G.V., McMillan S.A., and Hawkins S.A. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis. Immunol. Lett. 78 (2001) 183-187
6. Buttmann M., Merzyn C., Hofstetter H.H., and Rieckmann P. TRAIL, CXCL10 and CCL2 plasma levels during long-term interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J. Neuroimmunol. 190 (2007) 170-176
7. Ciusani E., Frigerio S., Gelati M., Corsini E., Dufour A., Nespolo A., La Mantia L., Milanese C., Massa G., and Salmaggi A. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 82 (1998) 5-12
8. Comi C., Leone M., Bonissoni S., DeFranco S., Bottarel F., Mezzatesta C., Chiocchetti A., Perla F., Monaco F., and Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 55 (2000) 921-927
9. Cvetkovic I., and Stosic-Grujicic S. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int. Immunopharmacol. 6 (2006) 1527-1534
10. Denkinger C.M., Denkinger M., Kort J.J., Metz C., and Forsthuber T.G. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol. 170 (2003) 1274-1282
11. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., and Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12 (2006) 47-57
12. Gomes A.C., Jonsson G., Mjornheim S., Olsson T., Hillert J., and Grandien A. Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 135 (2003) 126-134
13. Huang W.X., Huang M.P., Gomes M.A., and Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55 (2000) 928-934
14. Inoue A., Koh C.S., Sakai T., Yamazaki M., Yanagisawa N., Usuku K., and Osame M. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J. Neuroimmunol. 75 (1997) 141-146
15. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 (1999) 1451-1460
16. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
17. Lopatinskaya L., van Boxel-Dezaire A.H., Barkhof F., Polman C.H., Lucas C.J., and Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. J. Neuroimmunol. 138 (2003) 123-131
18. Mahovic D., Petravic D., Petelin Z., Zurak N., Horvat G., and Hajnsek S. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis. Clin. Neurol. Neurosurg. 106 (2004) 230-232
19. Martin-Villalba A., Herr I., Jeremias I., Hahne M., Brandt R., Vogel J., Schenkel J., Herdegen T., and Debatin K.M. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19 (1999) 3809-3817
20. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
21. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8 (2007) 913-919
22. Miura Y., Misawa N., Kawano Y., Okada H., Inagaki Y., Yamamoto N., Ito M., Yagita H., Okumura K., Mizusawa H., and Koyanagi Y. Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2777-2782
23. Niino M., Ogata A., Kikuchi S., Tashiro K., and Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J. Neurol. Sci. 179 (2000) 127-131
24. Nitsch R., Bechmann I., Deisz R.A., Haas D., Lehmann T.N., Wendling U., and Zipp F. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356 (2000) 827-828
25. Okuda Y., Apatoff B.R., and Posnett D.N. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J. Neuroimmunol. 171 (2006) 163-170
26. Santos R., Weinstock-Guttman B., Tamano-Blanco M., Badgett D., Zivadinov R., Justinger T., Munschauer III F., and Ramanathan M. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J. Neuroimmunol. 176 (2006) 125-133
27. Saresella M., Marventano I., Speciale L., Ruzzante S., Trabattoni D., Della Bella S., Filippi M., Fasano F., Cavarretta R., Caputo D., Clerici M., and Ferrante P. Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. J. Neuroimmunol. 166 (2005) 173-179
28. Sharief M.K. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J. Neuroimmunol. 109 (2000) 236-243
29. Wandinger K.P., Lunemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundstrom E., Ehrlich S., Wernecke K.D., Volk H.D., and Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361 (2003) 2036-2043
30. Wosik K., Biernacki K., Khouzam M.P., and Prat A. Death receptor expression and function at the human blood brain barrier. J. Neurol. Sci. 259 (2007) 53-60
31. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 301 (2000) 163-171
32. Zipp F., Otzelberger K., Dichgans J., Martin R., and Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J. Neuroimmunol. 86 (1998) 151-154
33. Zipp F., Weller M., Calabresi P.A., Frank J.A., Bash C.N., Dichgans J., McFarland H.F., and Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. 43 (1998) 116-120